AbbVie Inc. $ABBV Holdings Lifted by Anderson Hoagland & Co.

Anderson Hoagland & Co. grew its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 314.8% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 10,345 shares of the company’s stock after purchasing an additional 7,851 shares during the quarter. Anderson Hoagland & Co.’s holdings in AbbVie were worth $2,395,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Ellenbecker Investment Group boosted its position in AbbVie by 0.8% during the 3rd quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock worth $1,235,000 after acquiring an additional 44 shares during the period. Security National Bank of Sioux City Iowa IA raised its stake in shares of AbbVie by 0.3% during the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock valued at $3,562,000 after purchasing an additional 45 shares in the last quarter. Hobart Private Capital LLC lifted its holdings in AbbVie by 4.4% in the third quarter. Hobart Private Capital LLC now owns 1,127 shares of the company’s stock worth $261,000 after purchasing an additional 48 shares during the period. Rise Advisors LLC grew its position in AbbVie by 3.4% in the 3rd quarter. Rise Advisors LLC now owns 1,451 shares of the company’s stock valued at $336,000 after buying an additional 48 shares in the last quarter. Finally, Sivia Capital Partners LLC increased its stake in AbbVie by 1.1% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,571 shares of the company’s stock valued at $848,000 after buying an additional 51 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ABBV has been the subject of a number of research analyst reports. JPMorgan Chase & Co. upped their price target on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. BMO Capital Markets increased their price target on AbbVie from $215.00 to $240.00 and gave the company an “outperform” rating in a research note on Friday, September 12th. Berenberg Bank upgraded AbbVie from a “hold” rating to a “buy” rating and lifted their price target for the company from $170.00 to $270.00 in a research report on Wednesday, September 17th. Erste Group Bank lowered AbbVie from a “buy” rating to a “hold” rating in a report on Tuesday, October 14th. Finally, Evercore ISI lifted their target price on AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a report on Monday, September 22nd. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and a consensus target price of $245.84.

AbbVie Stock Performance

Shares of ABBV opened at $228.74 on Wednesday. The company has a 50-day moving average of $226.57 and a two-hundred day moving average of $211.87. The stock has a market cap of $404.28 billion, a price-to-earnings ratio of 173.29, a PEG ratio of 1.29 and a beta of 0.36. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter in the prior year, the firm earned $3.00 EPS. The firm’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a $1.73 dividend. The ex-dividend date is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. AbbVie’s dividend payout ratio is currently 496.97%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.